This content is intended for global healthcare professionals excluding those who are practising in the USA

Please confirm that you are a healthcare professional
practising outside of the USA


This medical activity has been sponsored by Merck. Merck provided financial support and video content, and has had input into the detailed project scope. This medical activity is hosted by Touch Medical Communications (TMC) for touchONCOLOGY.

Genitourinary Cancer View Time: 45 mins

touchSYMPOSIUM HIGHLIGHTS ESMO 2023: Putting patients first – cultivating care in bladder cancer

Watch leading genitourinary cancer experts Prof. Petros Grivas, Dr Enrique Grande, and Prof. Viktor Grünwald discuss evidence supporting the use of avelumab as first-line maintenance therapy in advanced urothelial cancer (UC), the current treatment landscape and best practice, and approaches to optimising patient experiences and outcomes.

  • Symposium Presentations
JAVELIN Bladder 100 trial – long-term efficacy overview by Prof. Petros Grivas
JAVELIN Bladder 100 trial – safety and quality of life outcomes
JAVELIN Bladder 100 trial – subgroup analyses
Real-world evidence of avelumab as first line maintenance therapy in advanced UC
First-line patient-based care in advanced UC – undertreatment and treatment guidelines by Dr Enrique Grande
The patient perspective in advanced UC
How can we meet patients’ needs in advanced UC?
Best treatment approaches in variant or non-UC histologies by Prof. Viktor Grünwald
Treating UC tumours in the upper urinary tract
Benefits of consolidation radiotherapy or surgery in UC
Sequencing and new options in the metastatic UC treatment landscape
Overview & Learning Objectives

A large proportion of patients with advanced or metastatic urothelial cancer (UC) do not receive systemic therapy, and there is an urgent need for effective and well tolerated treatment options that can be tailored to suit patient needs.1 In this activity, leading experts discuss the results of the JAVELIN Bladder 100 trial in advanced urothelial cancer, the current treatment landscape and best practice, and ways to optimise patient experiences and outcomes.

Learning Objectives

After watching this activity, participants should be better able to:

  • Summarise the key long-term outcomes from the JAVELIN Bladder 100 trial investigating avelumab as first-line maintenance therapy in advanced UC
  • Understand the key treatment needs from both the patient and physician’s perspective
  • Discuss current best practice and how new options may impact the advanced UC treatment landscape
Faculty & Disclosures
Prof. Petros Grivas

University of Washington, Fred Hutchinson Cancer Centre, Seattle, WA, USA

Prof. Petros Grivas is the Clinical Director of the Genitourinary Cancers Program at University of Washington and Seattle Cancer Care Alliance. He also led the bladder/urothelial cancer program at the Cleveland Clinic, USA. Prof Grivas has played a key role in pivotal clinical trials for several bladder/urothelial cancer treatments, and is actively involved in the ECOG-ACRIN co-operative research group, working with ASCO, ESMO and other international cancer organisations to further clinical and translational research.

Disclosures: Consultancy/advisory role for 4D Pharma PLC, Aadi Bioscience, AstraZeneca, Asieris Pharmaceuticals, Astellas Pharma, BMS, Boston Gene, CG Oncology, Dyania Health, Lucence Health, Fresenius Kabi, G1 Therapeutics, Gilead, Guardant Health, ImmunityBio, Infinity Pharmaceuticals, Janssen, Merck, MSD, Pfizer, PureTech, Roche, Seattle Genetics, Strata Oncology, Silverback Therapeutics, and UroGen. Institutional research funding from ALX Oncology, Acrivon Therapeutics, Bavarian Nordic, Bristol Myers Squibb, Debiopharm Group, G1 Therapeutics, Gilead Sciences, GSK, Merck, Mirati Therapeutics, MSD, Pfizer and QED Therapeutics.

Dr Enrique Grande

MD Anderson Cancer Centre, Madrid, Spain

Dr Enrique Grande, MD, PhD, MSc, is the Director of the Medical Oncology Program and Clinical Research Lead at the MD Anderson Cancer Centre Madrid, and the founder of the Spanish Group of Research on Orphan and Uncommon Tumours (GETHI). Dr Grande’s research focuses on genitourinary and endocrine tumours with the Translational Research and Early Drug Development Unit, and he has published over 200 manuscripts in peer-reviewed journals.

Disclosures: Honoraria for speaker engagements, advisory roles or funding of continuous medical education from Adium, Advanced Accelerator Applications, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Clovis-Oncology, Dr. Reddy’s, Eisai, Esteve, Eusa Pharma, GSK, IPSEN, ITM-Radiopharma, Janssen, Lilly, Merck, MSD, Novartis, ONCODNA (Biosequence), Palex, Pfizer, Raffo, Roche, Tecnofarma, Thermo Fisher Scientific, and Zodiac. Research Grants from Astra Zeneca, IPSEN, Lexicon, Merck, MTEM/Threshold/Tersera, Nanostring Technologies, Pfizer, and Roche. Commercial Medical Education provider for Universidad Francisco de Vitoria (UFV), Oncinfo, Permanyer and ACE Oncology.

Prof. Viktor Grünwald

University Hospital Essen, Essen, Germany

Prof. Viktor Grünwald is a professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in Essen, Germany. His main areas of research interest are in genitourinary cancers, with an emphasis on the academic development and translational research of immunotherapies in these indications.  Prof. Grünwald has also served on steering committees for genitourinary cancers at ESMO and ESMO ASIA Congresses and has been part of the scientific committees for the International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Haematology and Oncology (DGHO).

Disclosures: Invited speaker for Amgen, Astellas, AstraZeneca, BMS, EISAI, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, and Pfizer. Advisory Board member for Apogepha, BMS, Cureteq, Debiopharm, EISAI, EUSAPharm, Merck, MSD, Oncorena, PCI Biotech, Pfizer, and Roche. Stocks with AstraZeneca, BMS, MSD, and Seagen. Research Grants from BMS, Ipsen, MSD, and Pfizer. Travel support from Ipsen, Janssen-Cilag, Merck and Pfizer.

  1. Bharmal M, et al. Epidemiology of locally advanced or metastatic urothelial cancer in the US, Europe and Japan. Value in Health. 2017;20:PA419. doi:
Feedback Close

Please provide feedback for this touchSYMPOSIUM HIGHLIGHTS on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72